Skip to main content

Table 2 Parameter estimates in pediatric and young adult patients

From: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Parameter Pediatric/young adult model Adult model
Estimate %RSE Shrinkage (%) Estimate %RSE Shrinkage (%)
CL (L/day) 0.217 5   0.200 2  
V1 (L) 3.01 4   3.28 2  
V2 (L) 1.36 11   3.63 4  
Q (L/day) 0.183 18   0.546 8  
Weight on CL 0.795 8   0.808 8  
Albumin on CL −1.18 20   −1.12 10  
Tumor burden on CL 0.122 35   0.125 17  
Positive ADA on CL 1.23 8   1.16 25  
Weight on V1 0.766 8   0.559 8  
Albumin on V1 −0.566 29   −0.350 21  
Sex (female) on V1 NE   − 0.129 16  
Sex (female) on V2 NE   −0.272 16  
Proportional residual variance 0.051 32 12 0.043 7 9
Additive residual variance 68.9 109 12 16.6 39 9
BSV for CL 0.0458 33 21 0.0867 9 9
BSV for V1 0.0140 65 43 0.0328 18 17
BSV for V2 0.311 63 39 0.114 25 33
Correlation of BSVs for CL, V1 0.510   0.341   
Correlation of BSVs for CL, V2 NE   −0.236   
Correlation of BSVs for V1, V2 NE   0.434   
Objective function 3637    40,748   
  1. Abbreviations: %RSE Percent relative standard error, ADA Anti-drug antibody, BSV Between-subject variability, CL Clearance, NE Not evaluated, Q Inter-compartmental clearance, V1 Volume of the central compartment, V2 Volume of the peripheral compartment